Thu. 9 May 2024, 7:41am ET
Benzinga
Earnings, News
Cash, cash equivalents, and short-term investments were $135.3 million as of March 31, 2024, which are expected to provide financial runway through four Phase 2 clinical milestones and into mid-2026.